Full-Time

Key Account Manager

Confirmed live in the last 24 hours

Blueprint Medicines

Blueprint Medicines

501-1,000 employees

No salary listed

Senior

Aachen, Germany + 1 more

More locations: Wenden, Germany

Field-based position in West Germany, specifically in the Köln/Bonn/Aachen area.

Category
Strategic Account Management
Sales & Account Management
Required Skills
Data Analysis
Requirements
  • Understand the account situation, potential, challenges and needs
  • Formulate comprehensive, robust and insight-driven key account plans
  • Deliver on agreed objectives and tactics within the key accounts in order to drive BPM performance
  • Ensure account plans, objectives and KPIs are transparent to the team and senior leader
  • Manage the account plan execution according to agreed timelines and budget
  • Conduct market surveillance and communicate in-field intelligence on customer insights, external stakeholder activities and trends to key internal stakeholders
  • Support and collaborate with In-Field Market Access territory partner to gain product access to local formularies and/or protocols within own accounts
  • In coordination with supply chain, ensure product(s) is/are available at account level
  • Operate in a manner that is always in line with compliance and legal requirements and according to the marketing and sales strategies
  • Act as an ambassador of the BPM brand, its vision and values
  • Develop long-term relationships between BPM and key strategic accounts and their stakeholders
  • Identify key external stakeholders and develop deep understanding of their needs, collaborating on initiatives and co-creating mutually beneficial solutions that will add value to them and the patients
  • Drive the implementation of the innovative offerings with key stakeholders
  • Support and advise Healthcare professionals on the correct use of BPM product and services portfolio
  • Proactively coordinate collaboration with medical and market access (and other internal stakeholders) to ensure alignment in objectives and activities with accounts and external stakeholders
  • Monitor the account plan progress and hold collaborators, and self, accountable as agreed
  • Lead the core account team meetings and present account plans and progress at relevant local meetings to the management
  • Identify and address any collaboration misalignments
  • Prioritize and manage accounts within Switzerland by assessing appropriate business opportunities through contacts with key decision-makers and important local stakeholders
  • Systematically analyse success of plans (e.g. sales, market developments, competitors) and propose mitigating actions as needed
  • Make changes as needed based on new business opportunities and changes in the market place to achieve financial objectives
Responsibilities
  • Embrace and understand indications and scope account and HCPs for indicated territory
  • Implement programs to support the journey of patients and ultimately work with the local health care system to improve the treatment of this disease and/or the patient journey
  • Drive account stakeholder relationships; develop and monitor long-term relationships between Blueprint Medicines, the account and its key stakeholders
  • Design strategy for and be accountable for key accounts, develop concrete plans for those
  • Responsible for driving and achieving the business objectives of new product launches and in market assets
  • Responsible for leading and developing local strategic customer relationships and bring product to launch within compliance and legal requirements
  • Develop and execute projects initiated by relevant team members to support their customers, resulting in better and more efficient treatment outcomes helping Blueprint Medicines to be a key partner in the product area by stakeholders
  • Share insights and best practices within DACH team and within INT region
Desired Qualifications
  • Bachelor / Master’s degree in marketing or life science (preferably)
  • Minimum of 5 years of key account management experience in pharmaceutical industry
  • Experience in hematology and/or dermatology would be greatly appreciated
  • Experience in managing customer relationships across the full spectrum of customer types in healthcare industry
  • Account management experience
  • Knowledge in therapy and product area
  • Knowledge in National Healthcare system and the local and therapy specific policies that impact decision making
  • Fluent German and English, both written and oral
  • Strategic Approach Balances between the long-term vision while driving the short-term goals
  • Collaboration Establishes productive relationships and partners with others across the organization to ensure common understanding of objectives and achieve shared goals
  • Drive for Results Holds self and others accountable for delivering on commitments that align with our short- and long-term goals, never forgetting the end result is to help patients through innovation in medicine
  • Act with sense of urgency to address key stakeholder needs
  • Motivates and influences others to gain support for ideas, strategies and actions
  • Focuses on customer satisfaction and delivers a quality service or product to the agreed standards; understands the unmet needs of the patients
  • Integrates and drives the application of plans/tactics for functional strategy
  • Influences the functional strategy by defining, building, and communicating processes, relationships, and efficiencies in areas of accountability
  • Commitment to our Core Values: Patients First, Thoughtfulness, Urgency, Trust, Optimism

Company Size

501-1,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2011

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing demand for targeted therapies boosts Blueprint Medicines' market potential.
  • FDA initiatives expedite approval for Blueprint's innovative systemic mastocytosis treatments.
  • Increasing systemic mastocytosis prevalence aligns with Blueprint's therapeutic focus.

What critics are saying

  • Competition from Deciphera Pharmaceuticals' KIT inhibitor, ripretinib, poses a market threat.
  • Stringent European regulations may hinder Blueprint's market expansion.
  • Potential patent expirations could lead to generic competition and revenue loss.

What makes Blueprint Medicines unique

  • Blueprint Medicines leads in mast cell-targeted therapies with AYVAKIT and BLU-808.
  • AYVAKIT shows long-term efficacy and safety in treating indolent systemic mastocytosis.
  • BLU-808 offers a wide therapeutic window as a first-in-class oral KIT inhibitor.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Commuter Benefits

Mental Health Support

Employee Stock Purchase Plan

Parental Leave

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
ETF Daily News
Mar 8th, 2025
Proficio Capital Partners LLC Makes New $1.01 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC)

Proficio Capital Partners LLC makes new $1.01 million investment in Blueprint Medicines Co. (NASDAQ:BPMC).

Defense World
Mar 7th, 2025
Truist Financial Corp Makes New Investment in Blueprint Medicines Co. (NASDAQ:BPMC)

Truist Financial Corp makes new investment in Blueprint Medicines Co. (NASDAQ:BPMC).

Medical Update Online
Mar 4th, 2025
Blueprint Medicines highlights 'decade of leadership' in Mast Cell research with new AYVAKIT and BLU-808 data at AAAAI/WAO 2025

Blueprint Medicines highlights 'decade of leadership' in Mast Cell research with new AYVAKIT and BLU-808 data at AAAAI/WAO 2025.

PR Newswire
Feb 28th, 2025
Blueprint Medicines Highlights Leading Portfolio Of Mast Cell-Targeted Therapies At 2025 Aaaai / Wao Joint Congress

-- Updated data show AYVAKIT® (avapritinib) was safe and effective for long-term treatment of ISM, with sustained symptom and quality-of-life benefit and no new safety signals with multiple years of therapy ---- AYVAKIT-treated patients achieved improvements in bone health based on an analysis of bone mineral density scans, underscoring the importance of treating patients early in the ISM disease course ---- BLU-808 healthy volunteer trial results demonstrate wide therapeutic window for modulating mast cell activity, affirming potential as best- and first-in-class oral wild-type KIT inhibitor --CAMBRIDGE, Mass., Feb. 28, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations reflecting its ongoing efforts to innovate the treatment of mast cell-driven diseases. The presentations include three-year median follow-up data from the registrational PIONEER trial demonstrating the strong long-term efficacy and safety of AYVAKIT® (avapritinib) in patients with indolent systemic mastocytosis (ISM), and real-world evidence further characterizing the substantial burden of the disease, highlighting the urgency to treat. In addition, the company will report positive data from the Phase 1 healthy volunteer trial evaluating BLU-808, an investigational, highly potent and selective oral inhibitor of wild-type KIT, consistent with top-line data previously announced in January 2025. A total of 14 data presentations, including two oral presentations, will be reported at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) Joint Congress being held February 28-March 3 in San Diego."We are incredibly proud to showcase our mast cell therapy portfolio at AAAAI / WAO, with 14 presentations highlighting more than a decade of leadership and collaboration with the mast cell disease community, including renowned medical institutions pioneering innovative research and multi-disciplinary patient care," said Becker Hewes, M.D., Chief Medical Officer at Blueprint Medicines. "In ISM, new data have reinforced that AYVAKIT was very well-tolerated after multiple years of treatment, with a low discontinuation rate and safety results that have remained consistent with the safety profile from the placebo-controlled study as summarized in the FDA-approval label

Defense World
Feb 17th, 2025
Blueprint Medicines Corporation Reports Strong Financial Results for 2024

Furthermore, Blueprint Medicines announced the appointment of Sherwin Sattarzadeh as Chief Business Officer, succeeding Helen Ho.